Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. Before joining Xconomy, he was the national biotechnology reporter for Bloomberg News, based in San Francisco. There, he led coverage of major medical meetings like the American Society of Clinical Oncology and broke news about the industry’s top companies, including Amgen, Genentech, and Biogen Idec. His stories appeared in The New York Times, Los Angeles Times, and International Herald Tribune. From 2001 to 2006, his passionate coverage of the biotechnology industry won many awards for The Seattle Times.
While at the Times, Luke was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award, the Sigma Delta Chi prize from the Society of Professional Journalists, an honorable mention Gerald Loeb Award, and was nominated for the Pulitzer Prize in public service.
Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison. In 2005-2006, he was a Knight Science Journalism Fellow at MIT. In his spare time, Luke runs marathons, climbs mountains and roots for the Green Bay Packers.
-
[Update: 1:55 pm Eastern, 11/20/09] After a bitter standoff earlier this year with billionaire investor Carl Icahn over alleged mismanagement, Cambridge, MA-based Biogen Idec now faces another sharp... Read more »
-
Seattle-based Dendreon (NASDAQ: DNDN), the developer of what it hopes will be the first FDA-approved treatment to actively stimulate the immune system against cancer, said today the U.S. regulatory agency... Read more »
-
Seattle-based Omeros expects to apply for FDA clearance to start selling its first product by the second half of next year, and it also hoping to strike at least one partnership... Read more »
-
Waltham, MA-based ImmunoGen (NASDAQ: IMGN) said today that Amgen has purchased a second license to develop a treatment that uses ImmunoGen’s technology for linking targeted antibodies to cell-killing agents that... Read more »
-
San Diego-based Ligand Pharmaceuticals (NASDAQ: LGND) said today it has received $2 million in milestone payments as part of research collaboration with Merck that is due to expire next month.... Read more »
-
Few doctors knew much about a rare brain infection called PML back in 2005, when two patients on a hot new multiple sclerosis drug from Biogen Idec and Elan died from... Read more »
-
Three years have gone by since the region’s top biotech company was taken over by Eli Lilly, so it seemed like a good time to find out where all that talent... Read more »
-
Another day, another piece of bad news from Genzyme. The Cambridge, MA-based biotech giant (NASDAQ: GENZ) said today it is scrapping development of a next-generation drug for kidney disease after... Read more »
-
NanoString Technologies, the maker of a machine that lets scientists digitally analyze how genes are turned on or off in a tissue sample, just won a glowing endorsement from one... Read more »
-
[Update: 12:30 pm Pacific, 11/20/09] Icos was once the great hope for Seattle biotech. Founded in 1990 with an investment from Bill Gates, it went on over the next... Read more »
-
The big new cholesterol-lowering drug from Genzyme and Isis Pharmaceuticals, which both companies are counting on as a future profit driver, passed its first major clinical trial, but investors didn’t like... Read more »
-
[Updated: 5:55 pm Pacific, 11/16/09] Trubion Pharmaceuticals, the Seattle-based company developing new drugs for autoimmune diseases and cancer, said today that its founding CEO, Peter Thompson, has resigned... Read more »
-
Fate Therapeutics, the San Diego-based company on a quest to develop techniques that make stem cell research practical for the pharmaceutical industry, has raised $30 million in a Series B round... Read more »
-
San Diego-based Cadence Pharmaceuticals (NASDAQ: CADX) said today that the FDA has pushed back its deadline for reviewing the company’s intravenous pain reliever by three months. The FDA’s new deadline... Read more »
-
[Update: 6:22 pm Eastern, 11/13/09] Just when you thought it couldn’t get worse for Genzyme, it did. The FDA reported today that it has found tiny bits of garbage—steel,... Read more »
-
Qliance Medical Management, the Seattle-based company that operates primary care clinics that don’t accept insurance payments, has been selected for a one-year pilot program to offer services to members of... Read more »
-
Cequent Pharmaceuticals, the Cambridge, MA-based developer of RNA interference drug technology, said today it has filed an application with the FDA to begin the first clinical trial of an orally-delivered... Read more »
-
Seattle-based Oncothyreon (NASDAQ: ONTY) said it has decided to advance an experimental cancer drug into mid-stage clinical trials in the first half of 2010. The company plans to run two... Read more »
-
This was the week that a little biotech company in Bothell that few of the locals have ever heard of, burst onto the national stage.
—Bothell, WA-based Alder Biopharmaceuticals had its... Read more »
-
[Corrected: 7:26 am Pacific, 11/12/09] San Diego-based Altair Therapeutics, a company developing inhalable drugs to block inflammatory proteins involved in asthma and other respiratory diseases, has closed on the... Read more »
